BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38353066)

  • 1. Screening and prevention of ovarian cancer.
    Sideris M; Menon U; Manchanda R
    Med J Aust; 2024 Mar; 220(5):264-274. PubMed ID: 38353066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    Gaba F; Blyuss O; Chandrasekaran D; Osman M; Goyal S; Gan C; Izatt L; Tripathi V; Esteban I; McNicol L; Ragupathy K; Crawford R; Evans DG; Legood R; Menon U; Manchanda R
    BJOG; 2021 Mar; 128(4):714-726. PubMed ID: 32803845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
    Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
    Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical decision making in premenopausal
    Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
    J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
    JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
    Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
    Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
    Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.
    Hanley GE; Kwon JS; McAlpine JN; Huntsman DG; Finlayson SJ; Miller D
    Am J Obstet Gynecol; 2020 Aug; 223(2):221.e1-221.e11. PubMed ID: 32067967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
    Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
    Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.
    Johansen N; Liavaag AH; Tanbo TG; Dahl AA; Pripp AH; Michelsen TM
    Gynecol Oncol; 2016 Jan; 140(1):101-6. PubMed ID: 26597462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.
    Chandrasekaran D; Menon U; Evans G; Crawford R; Saridogan E; Jacobs C; Tischkowitz M; Brockbank E; Kalsi J; Jurkovic D; Manchanda R
    Fam Cancer; 2015 Dec; 14(4):521-30. PubMed ID: 26178205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.
    van Lieshout LAM; Steenbeek MP; De Hullu JA; Vos MC; Houterman S; Wilkinson J; Piek JM
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012858. PubMed ID: 31456223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?
    Boerner T; Long Roche K
    J Minim Invasive Gynecol; 2021 Mar; 28(3):403-408. PubMed ID: 33038519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging Salpingectomy as a Risk-Reducing Measure for Ovarian Cancer: Histopathological Analysis of the Tubo-Ovarian Interface in Women Undergoing Risk-Reducing Salpingo-oophorectomy.
    Ayres C; Ratnayake G; McNally O; Quinn M
    Int J Gynecol Cancer; 2017 May; 27(4):703-707. PubMed ID: 28399030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
    Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
    Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
    Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
    Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.
    Obstet Gynecol; 2019 Apr; 133(4):842-843. PubMed ID: 30913193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.